Format

Send to

Choose Destination
Sci Rep. 2014 Mar 27;4:4483. doi: 10.1038/srep04483.

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.

Author information

1
1] CSIR-Institute of Microbial Technology Chandigarh, India [2].
2
CSIR-Institute of Microbial Technology Chandigarh, India.

Abstract

Monoclonal antibody Trastuzumab/Herceptin is considered as frontline therapy for Her2-positive breast cancer patients. However, it is not effective against several patients due to acquired or de novo resistance. In last one decade, several assays have been performed to understand the mechanism of Herceptin resistance with/without supplementary drugs. This manuscript describes a database HerceptinR, developed for understanding the mechanism of resistance at genetic level. HerceptinR maintains information about 2500 assays performed against various breast cancer cell lines (BCCs), for improving sensitivity of Herceptin with or without supplementary drugs. In order to understand Herceptin resistance at genetic level, we integrated genomic data of BCCs that include expression, mutations and copy number variations in different cell lines. HerceptinR will play a vital role in i) designing biomarkers to identify patients eligible for Herceptin treatment and ii) identification of appropriate supplementary drug for a particular patient. HerceptinR is available at http://crdd.osdd.net/raghava/herceptinr/.

PMID:
24670875
PMCID:
PMC3967150
DOI:
10.1038/srep04483
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center